Emerging Treatment Options for Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma – Live

Description

Program Description

---

Click to Go to the Event Registration

CLL is a lymphoproliferative disease of neoplastic B cells, accumulating in the blood, bone marrow, lymph nodes, and spleen. CLL is the most common adult leukemia in Western countries. It is a disease of the elderly, with a median age at diagnosis of 72 years. As such, CLL clinical management is often challenging and highly individualized based on the age of patients, their comorbidities, and the biological features of CLL cells. During the past five years, rapid therapeutic advances have changed the landscape of CLL therapy.

MCL is a rare subtype of B-cell non-Hodgkin lymphomas (NHLs) characterized by a (1,14) translocation resulting in overexpression of the cyclin D1 (CCND1) gene. The variety of morphologic variants may make this a challenging diagnosis, although some cases are uncomplicated. It typically follows an aggressive clinical course (aggressive MCL), although an indolent leukemia variant (indolent MCL) has been described.

Agenda

---

• Clinical Vignette 1 (Pretest – Audience Response System)
• Discuss the pathophysiology and treatment options for CLL/SLL with Bruton tyrosine kinase (BKT) inhibitors and CAR T-cell therapies
• Clinical Vignette 1 (Posttest – Audience Response System)
• Clinical Vignette 2 (Pretest – Audience Response System)
• Discuss the pathophysiology and treatment options for MCL with BKT inhibitors and CAR T-cell therapies
• Clinical Vignette 2 (Posttest – Audience Response System)
• Questions from participants and panel discussion

Intended Audience

---

Hematologists/oncologists, nurse practitioners, physician assistants, and nurses.

Commercial Supporter

---

Supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC